E-LIB Suche - Ergebnisse für: Luminari S

1

Radioimmunotherapy versus autologous hematopoietic stem cel..:

Ladetto, M. ; Tavarozzi, R. ; Zanni, M....
Annals of Oncology. 35 (2024) 1 - p. 118-129 , 2024

Link: https://doi.org/10.1016/..

2

Long term outcome of Peripheral T Cell Lymphomas: 10y follo..:

Civallero, M. ; Advani, R. ; Horwitz, S....
Hematological Oncology. 41 (2023) S2 - p. 491-492 , 2023

Link: https://doi.org/10.1002/..

3

Baseline PET Total Metabolic Tumor Volume has a prognostic ..:

Skrypets, T. ; Chauvie, S. ; Manni, M....
Hematological Oncology. 41 (2023) S2 - p. 349-349 , 2023

Link: https://doi.org/10.1002/..

4

A gene expression signature to predict disease progression ..:

Donati, B. ; Nizzoli, M. E. ; Durmo, R....
Hematological Oncology. 41 (2023) S2 - p. 316-317 , 2023

Link: https://doi.org/10.1002/..

5

ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULA..:

Novelli, S. ; Luminari, S. ; Taszner, M....
Hematological Oncology. 41 (2023) S2 - p. 121-122 , 2023

Link: https://doi.org/10.1002/..

6

MARGINAL ZONE LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (MZL‐..:

Luminari, S. ; Bommier, C. ; Fabbri, N....
Hematological Oncology. 41 (2023) S2 - p. 102-103 , 2023

Link: https://doi.org/10.1002/..

7

The impact of spleen metabolic tumor volume on total metabo..:

Guerra, L. ; Chauvie, S. ; Marcheselli, L....
Hematological Oncology. 41 (2023) S2 - p. 339-340 , 2023

Link: https://doi.org/10.1002/..

8

Mature T and NK cell lymphomas classified according to 2016..:

Manni, M. ; Chiattone, C. S. ; Prince, M. H....
Hematological Oncology. 41 (2023) S2 - p. 311-312 , 2023

Link: https://doi.org/10.1002/..

9

P382 TEAMWORK IS SUCCESSFUL (2): PATIENT WITH DIFFUSE LARGE..:

Pennacchioni, A ; Nizzoli, M ; Roncali, M...
European Heart Journal Supplements. 25 (2023) Supplement_D - p. D195-D195 , 2023

Link: https://doi.org/10.1093/..

10

RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE I..:

Thieblemont, C. ; Lamy, T. ; Tani, M....
Hematological Oncology. 41 (2023) S2 - p. 104-106 , 2023

Link: https://doi.org/10.1002/..

11

COMBINED USE OF MINIMAL RESIDUAL DISEASE MONITORING AND FDG..:

Ferrero, S. ; Assanto, G. M. ; Durmo, R....
Hematological Oncology. 41 (2023) S2 - p. 183-185 , 2023

Link: https://doi.org/10.1002/..

12

Prognostic value of the end of induction PET in patients wi..:

Guerra, L. ; Bergesio, F. ; Fallanca, F....
Hematological Oncology. 41 (2023) S2 - p. 378-378 , 2023

Link: https://doi.org/10.1002/..

13

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDO..:

Sehn, L. H. ; Hübel, K. ; Luminari, S....
HemaSphere. 6 (2022) - p. 993-994 , 2022

Link: https://doi.org/10.1097/..

14

P1208: CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS WI..:

Chiattone, C. ; Civallero, M. ; Fischer, T....
HemaSphere. 6 (2022) - p. 1094-1095 , 2022

Link: https://doi.org/10.1097/..

15

S222: MATURE T AND NK CELL LYMPHOMAS CLASSIFIED ACCORDING T..:

Federico, M. ; Stepanishyna, Y. ; Skrypets, T....
HemaSphere. 6 (2022) - p. 123-124 , 2022

Link: https://doi.org/10.1097/..